Scientist II, ADC/AOC Conjugation

Key Responsibilities:

• Synthesis, purification, and characterization of antibody drug conjugates (ADCs) and antibody oligonucleotide conjugates (AOCs) on mg to gram scale under minimal supervision.
• Development, optimization, and validation of conjugation protocols specifically for antibody oligonucleotide conjugates.
• Optimization and validation of formulation buffers for bioconjugates.
• Lead application and refinement of automated techniques for ADC/AOC synthesis and purification.
• Collaboration with cross-functional teams to advance ADC/AOC discovery programs from conceptualization to early development.

Qualifications

• B.S. degree with 7 years of experience or M.S. degree with 5 years’ experience in Biochemistry, Organic, Bioorganic or Analytical Chemistry, Molecular Biology, or related field.
• Demonstrated hands-on expertise in laboratory-scale protein purification using Hydrophobic Interaction Chromatography (HIC), Size Exclusion Chromatography (SEC), Ion-Exchange (IEX), mixed-mode chromatography, and/or affinity chromatography. Experience with GE AKTA FPLC and Unicorn software is preferred.
• Hands-on experience with relevant analytical techniques such as HIC-HPLC, SEC, IEX, RP-HPLC, LCMS and capillary electrophoresis techniques (e.g., CE-SDS, icIEF).
• Strong experience in the discovery, design, synthesis, and purification of antibody drug conjugates (ADCs) and antibody oligonucleotide conjugates (AOC), including familiarity with associated chemistry and analytical methods.
• Proven ability to independently design experiments, troubleshoot technical issues, and deliver high-quality scientific output with attention to detail, and the ability to thrive in a fast-paced, cross-disciplinary team environment.
• Excellent written and oral communication skills, with a strong record of collaboration and innovation.

Preferred:

• Previous experience with linker chemistry and payload conjugation strategies specific to oligonucleotide therapeutics.
• Experience troubleshooting or optimizing the stability and delivery of antibody-oligonucleotide conjugates.